<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04013386</url>
  </required_header>
  <id_info>
    <org_study_id>R 36 / 2019</org_study_id>
    <nct_id>NCT04013386</nct_id>
  </id_info>
  <brief_title>Effects of Aprepitant/Dexamethasone Versus Mertazepine /Dexamethasone on Postoperative Nausea and Vomiting</brief_title>
  <official_title>Effects of Aprepitant/Dexamethasone Versus Mertazepine /Dexamethasone on Postoperative Nausea and Vomiting After Laparoscopic Sleeve Surgery: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Laparoscopic sleeve gastrectomy (LSG) is an emerging treatment modality among the various
      types of surgical approach to obesity (1). The incidence of PONV in obese patients undergoing
      bariatric surgery, who did not receive antiemetic prophylaxis, is high at nearly 70-80 %
      (2,3). Postoperatively, bariatric patients appear to suffer from nausea and vomiting more
      frequently than normal weight or obese patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, available interventions for PONV prophylaxis, especially as monotherapy, lack
      universal efficacy. Use of combination therapies with different pharmacological basis is
      likely to bring down rates of PONV. (6) Intravenous dexamethasone (8-10mg) reduces the
      incidence of PONV, minimizing activity of phospholipase A2 and blocking the expression of
      cyclooxygenase (COX)2 mRNA that reduce production of prostaglandin and control the release of
      endorphins.

      Aprepitant has demonstrated powerful additive effects when combined with dexamethasone and a
      5-HT3 to prevent both acute and delayed chemotherapy-induced nausea and vomiting (CINV), and
      in the prevention of postoperative nausea and vomiting (PONV) The use of mirtazapine in the
      management of nausea and vomiting has been reported for both treatment and premedication
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 15, 2019</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of aprepitant/dexamethasone versus mirtazapine/dexamethasone on PONV prophylaxis after laparoscopic sleeve surgery</measure>
    <time_frame>First 24 hours(h) postoperative.</time_frame>
    <description>Incidence (%) of nausea and vomiting in 24 hours(h) postoperative</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Nausea and Vomiting, Postoperative</condition>
  <arm_group>
    <arm_group_label>Aprepitant/Dexamethasone Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mertazepine /Dexamethasone Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprepitant and Dexamethasone</intervention_name>
    <description>Aprepitant capsule 80 mg and Dexamethasone 8 mg IVI</description>
    <arm_group_label>Aprepitant/Dexamethasone Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirtazapine and Dexamethasone</intervention_name>
    <description>Mirtazapine tablet 30 mg and Dexamethasone 8 mg IVI</description>
    <arm_group_label>Mertazepine /Dexamethasone Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone 8 mg IVI</description>
    <arm_group_label>Dexamethasone Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA physical status I or II

          -  Body mass index (BMI) â‰¥ 35 kg/cm-2

        Exclusion Criteria:

          -  Patients with gastrointestinal disorders,

          -  Patients with significant major organ disease,

          -  Patients received antidepressant drugs,

          -  Patients received an anti-emetic drug within 48 h before surgery,

          -  Patients on treatment with systemic glucocorticoids within 4 weeks before surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tarek Mohamed Ashoor, MD</last_name>
    <role>Study Director</role>
    <affiliation>Faculty of Medicine, Ain- shams University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ain-Shams University Hospitals</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>July 5, 2019</study_first_submitted>
  <study_first_submitted_qc>July 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2019</study_first_posted>
  <last_update_submitted>December 31, 2019</last_update_submitted>
  <last_update_submitted_qc>December 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Dr.Ibrahim Mamdouh Esmat</investigator_full_name>
    <investigator_title>Assistant Professor of Anesthesia and Intensive Care Department, Faculty of Medicine, Ain- shams University, Cairo, Egypt.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Mirtazapine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

